Pharma major Glenmark today said its US arm has received final approval from the US health regulator to market generic Levocetirizine Dihydrochloride tablets used for treating allergies in the American market.
"Glenmark Generics have been granted final approval for their Abbreviated New Drug Application (ANDA) from the United States Food and Drug Administration for Levocetirizine Dihydrochloride 5 mg tablets," Glenmark said in a filing to the Bombay Stock Exchange (BSE).
The tablets are generic version of UCB Inc's Xyzal tablets, it added.
Quoting IMS Health, Glenmark said: "Total US sales as reported by IMS Health for the 12-month period ending December 2010 were approximately $231 million."
Levocetirizine Dihydrochloride tablets are used for relief of symptoms associated with allergic rhinitis, which is an allergic inflammation of the nasal airways.
Shares of Glenmark were today trading at Rs 277.50 in the afternoon trade at BSE, down 1.63% from its previous close.
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors
Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share
Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor
Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements
Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app